Genome Editing Threat Assessment Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 9,062 other HR bills in the 116th — cohort avg 39d
Genome Editing Threat Assessment Act This bill requires the Department of Homeland Security (DHS) to develop a threat assessment of the potential homeland security vulnerabilities associated with genome modification and editing. Such assessment shall include information relating to the dual-use of emerging biotechnology; the ability of gene editing to maliciously proliferate infectious diseases and pandemics on human, animal, and plant populations; the cybersecurity vulnerabilities in computer systems analyzing genomic data; and privacy concerns associated with analyzing genomic data. Upon completion of the assessment, DHS shall make a determination if any changes to future DHS operations are required to address security vulnerabilities identified in such assessment. DHS shall report to the congressional homeland security committees on the findings of such threat assessment, recommendations, plans for incorporating such recommendations into future DHS operations, and proposed legislative changes.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2020 · fourth_quarter · Medical/Disease Research/Clinical Labs
Drug pricing, gene therapy, and rare disease funding generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Client expense: Not reported · Firm income: $20,000
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2020 · third_quarter · Medical/Disease Research/Clinical Labs
Drug pricing and gene therapy, generally; H.R. 4393 - Advancing Access to Precision Medicine; H.R. 2507/S. 2158 Newborn Screening Saves Lives Reauthorization Act; H.R. 8045 - Genome Editing Threat Assessment Act; HR 2501 - Medical Nutrition Equity Act;
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE